Sven-Erik Dahlén
Corporate Officer/Principal bei Karolinska Institutet
Aktive Positionen von Sven-Erik Dahlén
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Karolinska Institutet | Corporate Officer/Principal | - | - |
Karriereverlauf von Sven-Erik Dahlén
Ehemalige bekannte Positionen von Sven-Erik Dahlén
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | Direktor/Vorstandsmitglied | 01.01.2005 | 24.06.2010 |
Statistik
International
Schweden | 3 |
Operativ
Director/Board Member | 1 |
Corporate Officer/Principal | 1 |
Sektoral
Health Technology | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | Health Technology |
- Börse
- Insiders
- Sven-Erik Dahlén
- Erfahrung